Flag of the European Union EU Clinical Trials Register Help

Clinical trials for MabThera (rituximab)

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44337   clinical trials with a EudraCT protocol, of which   7367   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    436 result(s) found for: MabThera (rituximab). Displaying page 5 of 22.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2005-005216-24 Sponsor Protocol Number: DSHNHL2005-1 Start Date*: 2009-06-09
    Sponsor Name:University of Saarland
    Full Title: 14-daily Oxaliplatin, Gemcitabine, Dexamethasone and Rituximab with subsequent 90-Y-Zevalin-consolidation for the treamtent of aggressive CD-20-positive B-NHL-relapses in patients with inability to...
    Medical condition: Relapse or primary progress of aggressive CD-20-positive-B-NHL
    Disease: Version SOC Term Classification Code Term Level
    8.1 10052314 Lymphatic disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-001496-35 Sponsor Protocol Number: ISRCTN07963178 Start Date*: 2006-02-13
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust
    Full Title: A single centre, randomised controlled, open label study of rituximab as induction therapy in kidney transplantation.
    Medical condition: Renal Transplantation
    Disease: Version SOC Term Classification Code Term Level
    7.1 10038533 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-000854-32 Sponsor Protocol Number: RA 2.0 Start Date*: 2006-05-29
    Sponsor Name:Vienna Medical University
    Full Title: Rituximab in Rheumatoid Arthritis in Patients Who Failed Therapy With TNF-Blockers
    Medical condition: Rheumatoid Arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2010-019224-31 Sponsor Protocol Number: IGR2009/1593 Start Date*: 2012-06-06
    Sponsor Name:Institut Gustave Roussy
    Full Title: INTERGROUP TRIAL FOR CHILDREN OR ADOLESCENTS WITH B-CELL NHL OR B-AL: EVALUATION OF RITUXIMAB EFFICACY AND SAFETY IN HIGH RISK PATIENTS
    Medical condition: untreated advanced stage B-cell NHL or B-AL.
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067070 Follicular B-cell non-Hodgkin's lymphoma LLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006595 Burkitt's lymphoma PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067194 Burkitt's leukemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) FR (Completed) ES (Temporarily Halted) NL (Completed) HU (Completed) IT (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-003539-68 Sponsor Protocol Number: 2011/090/HP Start Date*: 2012-02-09
    Sponsor Name:CHU-HOPITAUX DE ROUEN
    Full Title: ETUDE PROSPECTIVE RANDOMISEE COMPARATIVE PREDNISONE/ CYCLOPHOSPHAMIDE VERSUS PREDNISONE/ RITUXIMAB AU COURS DE L'HEMOPHILIE ACQUISE
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10053745 Acquired haemophilia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-005011-10 Sponsor Protocol Number: RTX LD 2006 Start Date*: 2007-02-07
    Sponsor Name:UNIVERSITA DEGLI STUDI DI UDINE
    Full Title: LOW DOSE RITUXIMAB IN THE TREATMENT OF AUTOIMMUNE THROMBOCYTOPENIA.
    Medical condition: PATIENTS WITH AUTOIMMUNE THROMBOCYTOPENIA.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10050245 Autoimmune thrombocytopenia LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-012034-70 Sponsor Protocol Number: AGO/2009/004 Start Date*: 2009-06-03
    Sponsor Name:University Hospital Ghent
    Full Title: A protocol based treatment for debilitating fibrosing skin disorders with (anti-CD-20), rituximab
    Medical condition: Fibrosing skin disorders
    Disease:
    Population Age: Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-010998-20 Sponsor Protocol Number: HM09/8848 Start Date*: 2009-06-25
    Sponsor Name:Leeds Teaching Hospitals NHS Trust
    Full Title: Attenuated dose Rituximab with ChemoTherapy In CLL: A randomised, phase IIB trial in previously untreated patients with Chronic Lymphocytic Leukaemia (CLL) to compare fludarabine, cyclophosphamide ...
    Medical condition: Chronic Lymphocytic Leukaemia
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2004-002197-34 Sponsor Protocol Number: 04/Q1104/27 Start Date*: 2004-12-14
    Sponsor Name:University College London
    Full Title: A phase III multicentre randomised clinical trial comparing rituximab with CHOP given every 14 days and rituximab with CHOP given every 21 days for the treatment of patients with newly diagnosed d...
    Medical condition: Newly diagnosed diffuse large B cell non-Hodgkin's lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-003647-75 Sponsor Protocol Number: 28155 Start Date*: 2008-02-07
    Sponsor Name:Merck Serono International
    Full Title: A randomised, double-blind, placebo controlled, multi-centre, exploratory, pilot, phase II trial of 150 mg atacicept given subcutaneously in combination with rituximab in subjects with rheumatoid a...
    Medical condition: Rheumatoid arthritis.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) SE (Completed) GB (Prematurely Ended) FI (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-000128-22 Sponsor Protocol Number: FLIRT Start Date*: 2014-11-26
    Sponsor Name:LYSARC
    Full Title: A randomized phase III trial evaluating two strategies of rituximab administration for the treatment of first line/low tumor burden follicular lymphoma (Follicular Lymphoma IV/SC Rituximab Therapy)
    Medical condition: Stage II-IV follicular lymphoma grade 1-3a not previously treated
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10067070 Follicular B-cell non-Hodgkin's lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2012-003194-25 Sponsor Protocol Number: MabionCD20-001RA Start Date*: 2013-02-04
    Sponsor Name:Mabion S.A.
    Full Title: Randomized, Double-blind, Parallel-group Comparative Bioequivalence Trial of MabionCD20® (Mabion SA) Compared to MabThera® (rituximab, Roche) in Patients with Rheumatoid Arthritis
    Medical condition: Active Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2013-001245-14 Sponsor Protocol Number: CC-5013-NHL-007 Start Date*: 2013-12-13
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Placebo in Subjects With Relapsed/Refractory Indolent Lym...
    Medical condition: Relapsed/refractory indolent lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10060707 MALT lymphoma LLT
    20.0 100000004851 10041650 Splenic marginal zone lymphomas HLT
    20.0 100000004851 10029461 Nodal marginal zone B-cell lymphomas HLT
    20.0 100000004851 10016903 Follicle centre lymphomas, follicular grade I, II, III HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) CZ (Completed) IT (Completed) PT (Completed) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-001966-27 Sponsor Protocol Number: AGB002 Start Date*: 2016-09-07
    Sponsor Name:Archigen Biotech Limited
    Full Title: A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients w...
    Medical condition: Low Tumor Burden Follicular Lymphoma (LTBFL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed) GB (Completed) CZ (Completed) BG (Completed) FR (Completed) LV (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2007-000327-18 Sponsor Protocol Number: CLL 2007 FMP Start Date*: 2007-07-06
    Sponsor Name:GOELAMS
    Full Title: Phase III, multicenter, European, randomized trial comparing the combination Fludarabine-Cyclophosphamide-Rituximab (FCR) with the combination Fludarabine-Cyclophosphamide-Campath (FCCam) in previo...
    Medical condition: Rituximab and Campath are two antibodies directed against CD20 and CD52 antigen, respectively. The highest response rate in the B-CLL treatment has been obtained by the association of Fludarabine,...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009310 CLL LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-024004-98 Sponsor Protocol Number: DSHNHL2010-1 Start Date*: 2012-04-25
    Sponsor Name:University Medicine Göttingen Dept. Hematology and Oncology
    Full Title: Subcutaneous Rituximab and Intravenous Bendamustine in very Elderly Patients or Elderly Medically Non Fit Patients("slow go") with Aggressive CD-20-positive B-cell Lymphoma Short tiltle: BRENDA
    Medical condition: Very elderly or elderly medically non fit patients with aggressive CD20 positive B-cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003899 B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-002395-15 Sponsor Protocol Number: WA17047 Start Date*: 2006-01-09
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A randomized, phase 3, controlled, double-blind, parallel-group, multicenter study to evaluate the safety and efficacy of rituximab in combination with methotrexate (MTX) compared to MTX alone, in ...
    Medical condition: Rheumatoid arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) ES (Completed) DE (Completed) BE (Completed) SE (Completed) CZ (Completed) IT (Completed) GB (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-003314-41 Sponsor Protocol Number: GS-US-312-0133 Start Date*: 2014-08-05
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2, Single Arm Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia with 17p Deletion
    Medical condition: Chronic Lymphocytic Leukemia with 17p deletion
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10068919 B-cell chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) GB (Prematurely Ended) PT (Prematurely Ended) HU (Completed) IT (Completed) BE (Prematurely Ended) CZ (Prematurely Ended) DK (Prematurely Ended) ES (Completed) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-005021-48 Sponsor Protocol Number: TL011-RA-301 Start Date*: 2012-05-23
    Sponsor Name:Teva Pharmaceutical Industries
    Full Title: A multicenter, double-blind, randomized, active controlled, parallel-group study to evaluate the efficacy, safety, tolerability and pharmacodynamic profiles of TL011 infusions compared with MabTher...
    Medical condition: adult patients with severe, active rheumatoid arthritis patients treated with methotrexate (MTX)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) HU (Prematurely Ended) ES (Prematurely Ended) PL (Completed) BG (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-021184-32 Sponsor Protocol Number: GP13-201/GPN013A2301 Start Date*: 2010-11-30
    Sponsor Name:Hexal AG
    Full Title: A randomized, double-blind, controlled study to evaluate pharmacokinetics, pharmacodynamics, safety and efficacy of GP2013 and rituximab in patients with rheumatoid arthritis refractory or intolera...
    Medical condition: Refractory rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) ES (Completed) AT (Completed) IT (Completed) BE (Completed) EE (Completed) HU (Completed) PL (Completed) BG (Prematurely Ended) GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 22 08:05:27 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA